TY - JOUR
T1 - Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma
T2 - Long-term follow-up of a phase 1/2 study
AU - Gordon, Leo I.
AU - Molina, Arturo
AU - Witzig, Thomas
AU - Emmanouilides, Christos
AU - Raubtischek, Andrew
AU - Darif, Mohamed
AU - Schilder, Russell J.
AU - Wiseman, Greg
AU - White, Christine A.
PY - 2004/6/15
Y1 - 2004/6/15
N2 - We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.
AB - We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=2942595713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942595713&partnerID=8YFLogxK
U2 - 10.1182/blood-2003-11-3883
DO - 10.1182/blood-2003-11-3883
M3 - Article
C2 - 15016644
AN - SCOPUS:2942595713
SN - 0006-4971
VL - 103
SP - 4429
EP - 4431
JO - Blood
JF - Blood
IS - 12
ER -